Squarepoint Ops LLC Compugen LTD Transaction History

Squarepoint Ops LLC

$62.8 Billion
Q3 2024

A detailed history of Squarepoint Ops LLC transactions in Compugen LTD stock. As of the latest transaction made, Squarepoint Ops LLC holds 167,018 shares of CGEN stock, worth $257,207. This represents 0.0% of its overall portfolio holdings.

Number of Shares

167,018

Previous 85,693 94.9%

Holding current value

$257,207

Previous $143,000 111.19%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.56 - $2.1 $126,867 - $170,782	81,325 Added 94.9%	167,018 $302,000
Q2 2024 Aug 14, 2024	BUY	$1.68 - $2.52 $27,305 - $40,957	16,253 Added 23.41%	85,693 $143,000
Q1 2024 May 15, 2024	BUY	$1.75 - $2.95 $121,520 - $204,848	69,440 New	69,440 $179,000
Q3 2022 Nov 14, 2022	BUY	$0.66 - $2.32 $1,271 - $4,468	1,926 Added 17.67%	12,826 $8,000
Q2 2022 Aug 15, 2022	BUY	$1.57 - $3.33 $17,113 - $36,297	10,900 New	10,900 $20,000
Q1 2022 May 16, 2022	SELL	$2.76 - $4.64 $131,618 - $221,272	-47,688 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$4.09 - $7.16 $112,425 - $196,814	-27,488 Reduced 36.56%	47,688 $205,000
Q3 2021 Nov 15, 2021	SELL	$5.8 - $8.02 $403,210 - $557,542	-69,519 Reduced 48.05%	75,176 $449,000
Q2 2021 Aug 16, 2021	BUY	$6.87 - $9.16 $847,517 - $1.13 Million	123,365 Added 578.36%	144,695 $1.2 Million
Q1 2021 May 17, 2021	BUY	$7.67 - $13.77 $163,601 - $293,714	21,330 New	21,330 $183,000
Q4 2020 Feb 16, 2021	SELL	$12.07 - $17.95 $799,371 - $1.19 Million	-66,228 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$14.16 - $19.45 $937,788 - $1.29 Million	66,228 New	66,228 $1.08 Million

Others Institutions Holding CGEN

# of Institutions

Shares Held

13.1M

Call Options Held

79.2K

Put Options Held

12.7K

View Full List

About COMPUGEN LTD

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $133M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

More about CGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.

Account

Squarepoint Ops LLC Compugen LTD Transaction History